Compare Tencent Music Entertainment Group - ADR (TME) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tencent Music Entertainment Group - ADR vs Twist Bioscience Corp — how do they compare? Tencent Music Entertainment Group - ADR trades at $8.38 (market cap $12.83B), while Twist Bioscience Corp trades at $160.15 (market cap $10.08B). The key difference: Tencent Music Entertainment Group - ADR is the larger of the two by market cap, and Tencent Music Entertainment Group - ADR pays a 3.02% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tencent Music Entertainment Group - ADR for 67 Days and Twist Bioscience Corp for 27 Days on average.
| TME | TWST | |
|---|---|---|
Market Cap | $12.83B | $10.08B |
Volume | 3,618,478 | 4,229,037 |
Sector | Media | Health |
52-Week High | $23.71 | $205.00 |
52-Week Low | $7.74 | $25.45 |
Typical Hold Time | 67 Days | 27 Days |
Enterprise Value | $10.77B | $10.01B |
Dividend Yield | 3.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TME trades at $8.38, up 4.88% today, but technical indicators are bearish overall. The company reported strong 2025 results with revenue of $32.9B and net income of $11.06B, though recent quarters show mixed earnings performance. Analyst sentiment is mixed with a consensus price target of $12.50, and the stock appears undervalued with a P/E of 9.33 and P/S of 2.46.
The outlook is balanced: attractive valuation and profitability support upside potential, but bearish technicals, competitive pressures, and recent net cash outflows pose risks. Investors should weigh strong fundamentals against near-term headwinds and market sentiment.
Twist Bioscience (TWST) trades at $162.43, up 4.36% today, showing strong momentum despite recent earnings misses. The stock maintains a bullish technical signal with RSI at 29.02 indicating potential oversold conditions. Fundamentally, revenue growth continues (2025: $377M, 2026: $432M projected) but profitability remains elusive with negative margins. Recent partnership with Eli Lilly's TuneLab platform highlights strategic positioning in AI-driven drug discovery.
While analyst consensus favors Buy (73%), the stock trades above the $145.20 target, suggesting limited near-term upside. Key risks include persistent cash burn (-$44M net CF in 2025) and high valuation multiples (P/S: 21.5). The AI biotech partnership provides growth catalyst potential, but profitability timeline remains uncertain for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tencent Music Entertainment Group - ADR
TME is the largest online music service provider in China. It was founded in 2016 with the business combination of QQ Music (founded in 2005), Kuwo Music (founded in 2005) and Kugou Music (founded in 2004) streaming platforms. Tencent is the largest shareholder of TME with over 50% shares and over 90% voting rights held. TME also provides social entertainment services, including music live audio/video broadcasts and online concert services through the three platforms mentioned above, and online karaoke through an independent platform WeSing.
Read more on TME →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
